Rating Change
Baird analysts downgraded Contineum Therapeutics, Inc. Class A Common Stock (NASDAQ:CTNM) from Outperform to Neutral on October 14, 2026.
downgradeNASDAQ:CTNM
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Downgraded to Neutral by Baird
Baird analysts downgraded Contineum Therapeutics, Inc. Class A Common Stock (NASDAQ:CTNM) from Outperform to Neutral on October 14, 2026.
At publication ·
What changed
Contineum Therapeutics, Inc. Class A Common Stock (NASDAQ:CTNM) · downgrade
- Firm
- Baird
- Rating
- Outperform to Neutral
- Price at event
- $8.04
- Market capitalization
- $383.1M
At a glance
Key takeaways
- Baird downgraded Contineum Therapeutics (CTNM) from Outperform to Neutral on October 14, 2026.
Market Context
Contineum Therapeutics, Inc. Class A Common Stock operates in the Healthcare sector. The stock currently trades at $8.04 with a market capitalization of $383.1M.
Analyst downgrades can weigh on a stock in the short term as institutional investors who follow Baird's research adjust their positions. However, downgrades also sometimes create buying opportunities if the market overreacts to the rating change. The reasoning behind the downgrade matters more than the rating itself.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Contineum Therapeutics, Inc. Class A Common Stock
Among the 10 most recent ratings: 6 Buy, 4 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 14, 2026 | Baird | Neutral | N/A |
| Sep 28, 2026 | Morgan Stanley | Equal-Weight | N/A |
| Sep 15, 2026 | Jones Trading | Buy | N/A |
| Sep 15, 2026 | Baird | Outperform | N/A |
| Jul 31, 2026 | RBC Capital | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View CTNM Stock Page
Frequently Asked Questions
What does the Neutral rating mean for CTNM?
A rating of Neutral from Baird reflects the analyst's outlook on Contineum Therapeutics, Inc. Class A Common Stock (NASDAQ:CTNM). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the CTNM forecast page.